Study Evaluating Prevenar Vaccine in Healthy Infants
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine the immunogenicity of Prevenar in infants immunized at 2, 4 and 6 months of age. To determine the antibody responses to the seven pneumococcal vaccine serotypes one month after second dose and determine the safety of Prevenar in infants immunized at 2,4 and 6 months of age.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
42 Days to 100 Days (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy male and female children 2 months of age (42 to 100 days) in good health.
An informed consent must be signed by a parent or legal guardian following a detailed explanation of participation in the study.
Infants whose parent(s)/guardian(s) will be available for the entire study period.
Hypersensitivity to any component of the vaccine, including diphtheria toxoid
Infants with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection
Infants with known or suspected impairment of immunologic functions including HIV or those receiving immunosuppressive therapy.